Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03090789 · ClinicalTrials.gov registry record
FA Clinical Outcome Measures
A clinical trial of Friedreich Ataxia and Neuro-Degenerative Disease, sponsored by Friedreich's Ataxia Research Alliance.
- Active
- Registry status
- 2,000
- Enrollment target
- 14
- Study locations
NCT03090789: Active study of Friedreich Ataxia and Neuro-Degenerative Disease, sponsored by Friedreich's Ataxia Research Alliance.
NCT03090789 is a study of Friedreich Ataxia and Neuro-Degenerative Disease that is active but no longer recruiting, run by Friedreich's Ataxia Research Alliance. The registered enrollment target is 2,000 participants, above the 307-participant average among 14 other Friedreich Ataxia trials with a reported enrollment target (551% higher). The trial reports 14 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03090789, a study of Friedreich Ataxia and Neuro-Degenerative Disease, is active but no longer recruiting, sponsored by Friedreich's Ataxia Research Alliance.
- ACTIVE NOT RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 14
- Study locations
Study Summary
This multicenter natural history study aims to expand the network of clinical research centers in FA, and to provide a framework for facilitating therapeutic interventions. In addition, this study will lead to the development of valid yet sensitive clinical measures crucial to outcome assessment of patients with Friedreich's Ataxia. This study will support genetic modifier studies, biomarker studies, and frataxin protein level assessments by building a sample repository. This natural history study is no longer recruiting under this protocol NCT03090789 but remains actively recruiting under the harmonized study (UNIFAI) NCT06016946.
Primary Outcome
rating scale based on clinical neurologic examination
Conditions Studied
Study Locations (14)
Florida
- University of Florida - Neurology - Gainesville
- USF Ataxia Research Center - Tampa
Other
- All India Institute of Medical Sciences (Aiims) - New Delhi
- Auckland City Hospital - Auckland
California
- UCLA Ataxia Center - Los Angeles
Colorado
- University of Colorado - Denver
Georgia
- Emory University Hospital - Neurology - Atlanta
Iowa
- University of Iowa, Stead Family Children's Hospital - Iowa City
Ohio
- Ohio State University - Neurology - Columbus
Pennsylvania
- Children's Hospital of Philadelphia - Neurology - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2001-01-01 |
| Est. Completion | 2030-01-01 |
What the registry record for NCT03090789 still lists
NCT03090789 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 307-participant average among 14 other Friedreich Ataxia trials with a reported enrollment target (551% higher).
The record links to 2 conditions, with Friedreich Ataxia appearing as the primary indexed condition, and to 0 interventions.
NCT03090789 lists 14 locations in 12 states (Florida, Other, California).
Frequently Asked Questions
What is clinical trial NCT03090789 about?
NCT03090789 is a clinical study titled "FA Clinical Outcome Measures". This multicenter natural history study aims to expand the network of clinical research centers in FA, and to provide a framework for facilitating therapeutic interventions. In addition, this study will lead to the development of valid yet sensitive clinical measures crucial to outcome assessment of ...
What is the current status of trial NCT03090789?
This trial is currently active not recruiting. The enrollment target is 2,000 participants. The study started on 2001-01-01. Estimated completion is 2030-01-01.
What conditions does trial NCT03090789 study?
This clinical trial studies the following conditions: Friedreich Ataxia, Neuro-Degenerative Disease.
Who is sponsoring clinical trial NCT03090789?
This trial is sponsored by Friedreich's Ataxia Research Alliance, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03090789 being conducted?
This trial has 14 study locations across California, Colorado, Florida, Georgia, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Friedreich Ataxia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03090789's enrollment target sits among peer trials
2,000 2nd of 14 the highest of 14 other Friedreich Ataxia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Friedreich Ataxia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Course Of Disease In Participants With FA-CM
RECRUITING
-
A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors
RECRUITING
-
A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
RECRUITING · Phase 1
-
Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia
RECRUITING · Phase 1
-
A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies
RECRUITING
-
A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (BRAVE)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI